Nattawat Klomjit (@basmeomeo) header
Nattawat Klomjit (@basmeomeo) profile picture

Someone who love kidneys and physiology😷| He, him, his.

Minneapolis, MN
Joined March 2017
Photo by Nattawat Klomjit (@basmeomeo)Photo by Nattawat Klomjit (@basmeomeo)Photo by Nattawat Klomjit (@basmeomeo)Photo by Nattawat Klomjit (@basmeomeo)Photo by Nattawat Klomjit (@basmeomeo)Photo by Nattawat Klomjit (@basmeomeo)Photo by Nattawat Klomjit (@basmeomeo)Photo by Nattawat Klomjit (@basmeomeo)Photo by Nattawat Klomjit (@basmeomeo)Photo by Nattawat Klomjit (@basmeomeo)
Nattawat Klomjit retweeted
Two Reviews @NEJM Twenty years apart Two great colleagues Bob Kyle and Shaji Kumar
7
27
1
296
21,367
Nattawat Klomjit retweeted
In our new study in KI Reports we show how longitudinal monitoring of serum anti-podocin antibodies guided immunotherapy in a difficult case of steroid- and rituximab-resistant nephrotic syndrome sciencedirect.com/science/ar…
5
23
55
2,412
🧬Introducing our first-ever handbook of genetic nephrology, with free download until 8/2025 authors.elsevier.com/a/1lSgW… @AndrewMallett8 and I saw a gap in foundational reading of genetic nephrology and decided to gather articles that clinician and learners can all enjoy
15
59
1
144
15,705
Nattawat Klomjit retweeted
#Complement Activation in Secondary Thrombotic Microangiopathies (#TMA) āœ… Final version available in #OpenAccess in @NDTsocial āž”ļø academic.oup.com/ndt/advance… šŸ™ experts, colleagues and friends; the @ERAkidney Immunonephrology Working Group; and @AKronbichler for your leadership!
5
51
132
7,570
Nattawat Klomjit retweeted
The International Myeloma Working Group (IMWG) develops criteria for diagnosis, risk-strat, & response, provides current treatment guidelines, conducts collaborative research Bookmark our website: IMWG experts searchable by name and region IMWG.org @IMFmyeloma
1
23
4
97
9,554
Nattawat Klomjit retweeted
Sorry I accidentally deleted the original post while trying to answer some questions. I’m still a novice with X 😁 Take home message: small ~3% of PLA2R negative MN cases by routine IF are PLA2R positive by LMD/MS. kidney-international.org/art…
3
18
72
6,087
Stunning interim results from the VISIONARY Phase 3 trial in IgA nephropathy! Sibeprenlimab 400 mg led to a 51.2% placebo-adjusted reduction in 24h proteinuria (uPCR), with a -50.2% absolute reduction at 9 months! šŸ”µ Placebo barely moved the needle: +2.1%. šŸ“‰ Early and sustained drop in spot uPCR confirmed. šŸŽÆ A real game-changer on the horizon? #ERA2025 #IgAN #Nephrology #Proteinuria #VISIONARYtrial #Sibeprenlimab #ClinicalTrials #GlomerularDisease #KidneyHealth #PrecisionMedicine
2
6
1
37
186,374
More than 50% reduction in uacr with combo and about 30% with each component that is empagliflozin and finerenone. Time to consider simultaneous initiation of combination therapy in ckd and t2d as in hfref and stage 2 hypertension.
šŸ”„ #CONFIDENCE in @NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 nejm.org/doi/full/10.1056/NE…
4
43
3
84
8,942
Nattawat Klomjit retweeted
Just out. Updated myeloma mSMART guidelines on prevention and management of bispecific antibody associated Toxicities. @YiLinMDPhD @MayoMyeloma #ASCO25 Comprehensive and covers CRS, neurotoxicity, infection prevention and more. Link: msmart.org/mm-treatment-guid…
4
83
4
203
22,105
The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy @LadanZand @basmeomeo @mvargas07 @SethiRenalPath @fervenzafernan1 kidney-international.org/art…
10
20
1,383
Nattawat Klomjit retweeted
The remarkable story of Velcade. In the year 2000, a few of us attended an angiogenesis meeting in Boston. We were there to discuss thalidomide But a side meeting that evening led to trial that went on to get Velcade FDA approved for myeloma. @NEJM Story in thread.
10
104
13
340
58,832
Nattawat Klomjit retweeted
Thank you @basmeomeo for coming all of the way to Boston to share your expertise!
3
1
4
273
ANCA-negative pauci-immune GN is reported to occur in up to 30% of cases; in Europe, it has a prevalence of 1-5% of cases. Our multi-centre series reported the largest cohort of 132 cases and was just published in @KIReports kireports.org/article/S2468-… Baseline char. are given!
2
41
1
94
4,819
Nattawat Klomjit retweeted
Anti-slit diaphragm antibodies in autoimmune podocytopathy: •Anti-nephrin → frequent in kids •Anti-podocin → in kids & adults •Anti-Kirrel1 → more rare •Some patients have multiple autoantibodies. journals.lww.com/jasn/citati…
10
84
5
160
16,612
Nattawat Klomjit retweeted
Optimal Glucocorticoid Therapy in Lupus Nephritis doi.org/10.1093/ndt/gfae294
52
161
9,064
Amazing how Inebilizumab transforms IgG4RD into a controllable disease! Congratulations to my colleague Prof John Stone and team to this landmark trial!
We've already seen remarkable results for lupus and other autoimmune diseases with CD19 B cell depletion therapy. Now add IgG4 related disease (which has no treatment) in a new randomized trial @NEJM nejm.org/doi/full/10.1056/NE…
1
9
42
2,679
#Tirzepatide SURMOUNT-1 three year efficacy outcomes just presented at #ObesityWeek2024 šŸ‘€ šŸ“‰Sustained weight loss of 22.9% or an average 54lbs over 3 years šŸ”½94% reduction in risk of progression to diabetes. Number Needed to Treat = 9 🤯 šŸ«€Improvement in metabolic parameters This is the longest trial duration studying tirzepatide to date
5
113
10
336
38,287
Nattawat Klomjit retweeted
A super review of engineered T cells for cancer (CAR T and TILs) jamanetwork.com/journals/jam… @JAMA_current @BrudnoN @MarcelaMaus @CSHinrichsMD
4
212
5
775
97,465